On Nov. 20, 2020, Eli Lilly announced that Health Canada had granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who are at high risk of progressing to severe COVID-19 illness and/or hospitalization.